Cost effectiveness and strategic planning (WHO-CHOICE)

AFR E: Cost effectiveness results for Malaria

This Table provides summary results of the total population-level costs, effects and cost-effectiveness for the selected WHO sub-region and risk factor / disease for the year 2000.

KEY
I$ - International Dollars
Program Costs include costs of administration, media, training etc
Patient Costs include costs of hospital visits, drugs, etc
Incremental cost-effectiveness ratio (ICER) is defined as the incremental change in cost, divided by the incremental change in effectiveness. ICERs are reported for the successive set of interventions that would be selected at expanding levels of resource availability, starting with the intervention with the lowest cost per DALY averted, then moving to the next most cost-effective combination intervention out of the remaining available set of interventions.
Dominated is used to denote an intervention that is more costly and/or less effective than other, more efficient (single or combined) interventions; i.e. dominated interventions do not appear on the expansion path of most cost-effective strategies.


Interventions:Codes_and_Descriptions Coverage Cost per year (I$, millions) per one million_population [i.e. cost per capita] % Program costs % Patient costs DALYs averted per year per one million_population Average Cost per DALY averted Incremental Cost per DALY averted
MAL-1 : Insecticide-treated bed nets (ITN) 95% 0.71 17,101 41 Dominated
MAL-2 : Intermittent presumptive treatment in pregnancy (IPTP) 95% 0.06 170 352 Dominated
MAL-3 : Indoor residual spraying (IRS) 95% 0.71 17,101 41 Dominated
MAL-4: Case management with chloroquine (CQ) 95% 0.21 7,247 29 Dominated
MAL-5 : Case management with sulfadoxine-pyrimethamine (SP) 95% 0.21 11,895 17 Dominated
MAL-6 : Case management with non-artemisinin-based combination therapy (Comb) 95% 0.21 12,970 16 Dominated
MAL-7 : Case management with artemisinin-based combination therapy (ACT) 95% 0.21 17,037 12 12
MAL-8 : Combination (ITN & CQ) 95% 0.82 21,088 39 Dominated
MAL-9 : Combination (ITN & SP) 95% 0.73 23,637 31 Dominated
MAL-10 : Combination (ITN & Combo) 95% 0.82 24,226 34 Dominated
MAL-11 : Combination (ITN & ACT) 95% 0.74 26,450 28 56
MAL-12 : Combination (IRS & CQ) 95% 0.85 21,088 40 Dominated
MAL-13 : Combination (IRS & SP) 95% 0.85 23,637 36 Dominated
MAL-14 : Combination (IRS & Combo) 95% 0.85 24,226 35 Dominated
MAL-15 : Combination (IRS & ACT) 95% 0.86 26,450 32 Dominated
MAL-16: Combination (IRS & ACT & IPTP) 95% 0.86 26,485 33 Dominated
MAL-17: Combination (ITN & ACT & IPTP) 95% 0.83 26,485 31 Dominated
MAL-18: Combination (IRS & ITN) 95% 1.21 25,314 48 Dominated
MAL-19: Combination (IRS & ITN & ACT) 95% 1.28 31,032 41 118
MAL-20: Combination (IRS & ITN & ACT & IPTP) 95% 1.28 31,054 41 151
MAL-21: Insecticide-treated bed nets (ITN) 80% 0.63 14,925 42 Dominated
MAL-22: Intermittent presumptive treatment in pregnancy (IPTP) 80% 0.06 146 391 Dominated
MAL-23: Indoor residual spraying (IRS) 80% 0.60 14,925 40 Dominated
MAL-24: Case management with chloroquine (CQ) 80% 0.20 6,230 32 Dominated
MAL-25: Case management with sulfadoxine-pyrimethamine (SP) 80% 0.20 10,221 20 Dominated
MAL-26: Case management with non-artemisinin-based combination therapy (Comb) 80% 0.20 11,144 18 Dominated
MAL-27: Case management with artemisinin-based combination therapy (ACT) 80% 0.20 14,632 14 Dominated
MAL-28: Combination (ITN & CQ) 80% 0.73 18,605 39 Dominated
MAL-29: Combination (ITN & SP) 80% 0.82 20,957 39 Dominated
MAL-30: Combination (ITN & Combo) 80% 0.73 21,500 34 Dominated
MAL-31: Combination (ITN & ACT) 80% 0.82 23,551 35 Dominated
MAL-32: Combination (IRS & CQ) 80% 0.74 18,605 40 Dominated
MAL-33: Combination (IRS & SP) 80% 0.74 20,957 36 Dominated
MAL-34: Combination (IRS & Combo) 80% 0.74 21,500 35 Dominated
MAL-35: Combination (IRS & ACT) 80% 0.75 23,551 32 Dominated
MAL-36: Combination (IRS & ACT & IPTP) 80% 0.75 23,584 32 Dominated
MAL-37: Combination (ITN & ACT & IPTP) 80% 0.74 23,584 31 Dominated
MAL-38: Combination (IRS & ITN) 80% 1.05 22,374 47 Dominated
MAL-39: Combination (IRS & ITN & ACT) 80% 1.11 28,014 40 Dominated
MAL-40: Combination (IRS & ITN & ACT & IPTP) 80% 1.12 28,035 40 Dominated
MAL-41: Insecticide-treated bed nets (ITN) 50% 0.47 9,589 49 Dominated
MAL-42: Intermittent presumptive treatment in pregnancy (IPTP) 50% 0.05 91 596 Dominated
MAL-43: Indoor residual spraying (IRS) 50% 0.39 9,589 40 Dominated
MAL-44: Case management with chloroquine (CQ) 50% 0.19 3,888 49 Dominated
MAL-45: Case management with sulfadoxine-pyrimethamine (SP) 50% 0.19 6,372 30 Dominated
MAL-46: Case management with non-artemisinin-based combination therapy (Comb) 50% 0.19 6,946 27 Dominated
MAL-47: Case management with artemisinin-based combination therapy (ACT) 50% 0.19 9,112 21 Dominated
MAL-48: Combination (ITN & CQ) 50% 0.56 12,195 46 Dominated
MAL-49: Combination (ITN & SP) 50% 0.67 13,859 49 Dominated
MAL-50: Combination (ITN & Combo) 50% 0.56 14,243 39 Dominated
MAL-51: Combination (ITN & ACT) 50% 0.68 15,691 43 Dominated
MAL-52: Combination (IRS & CQ) 50% 0.53 12,195 44 Dominated
MAL-53: Combination (IRS & SP) 50% 0.53 13,859 38 Dominated
MAL-54: Combination (IRS & Combo) 50% 0.53 14,243 37 Dominated
MAL-55: Combination (IRS & ACT) 50% 0.53 15,691 34 Dominated
MAL-56: Combination (IRS & ACT & IPTP) 50% 0.53 15,714 34 Dominated
MAL-57: Combination (ITN & ACT & IPTP) 50% 0.56 15,714 36 Dominated
MAL-58: Combination (IRS & ITN) 50% 0.73 14,711 50 Dominated
MAL-59: Combination (IRS & ITN & ACT) 50% 0.78 19,112 41 Dominated
MAL-60: Combination (IRS & ITN & ACT & IPTP) 50% 0.78 19,129 41 Dominated
Share